Launch of Nasodine promotion to HCPs in Singapore

  31 Oct 2024

Firebrick Pharma (ASX:FRE) is pleased to announce that it has executed a Marketing Representation Agreement with Singapore-based, Innorini Pte Ltd, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services”…

Read More